Observation on Dosage Optimization and Safety Advantages of Oliceridine Fumarate Injection for Painless Fiberoptic Bronchoscopy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600124266

Enrollment

Unknown

Registered

2026-05-09

Start date

2026-05-11

Completion date

Unknown

Last updated

2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Diseases

Interventions

Oliceridine Group:Adjust the dosage of oliceridine

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18–75 years; 2.ASA physical status I–III; 3.scheduled for elective painless fiberoptic bronchoscopy; 4.expected procedure duration 15–45 minutes; 5.signed informed consent form.

Exclusion criteria

Exclusion criteria: 1. Hypersensitivity to oliceridine or opioids; 2. Severe cardiopulmonary disease (LVEF = 28; 7. Patients with difficult airway or severe obstructive sleep apnea syndrome.

Design outcomes

Primary

Measure	Time frame
Oliceridine dose;	—

Secondary

Measure	Time frame
Incidence of nausea and vomiting within 24 hours postoperatively;Recovery time;Total dose of propofol;Duration of bronchoscopy;	—

Countries

China

Contacts

Public ContactZhang Yiwei

The First Affiliated Hospital of Ningbo University

fyyzhangyiwei@nbu.edu.cn+86 177 5746 1135

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 16, 2026